Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Trevena, Inc. (NASDAQ:TRVN)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.80 and traded as high as $1.83. Trevena shares last traded at $1.76, with a volume of 6,213 shares.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. StockNews.com initiated coverage on shares of Trevena in a research note on Saturday. They set a “sell” rating on the stock. HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Trevena in a research report on Thursday, November 14th.

Trevena Price Performance

The firm’s fifty day moving average is $1.80 and its 200 day moving average is $4.11. The firm has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million for the quarter. Equities research analysts forecast that Trevena, Inc. will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.